Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | DRD4 | P21917 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29035907 | 0.83 | CA1 (0.38) | CA1CA2DRD1MAPK1DRD2 | |
| SCHEMBL1243001 | 0.82 | PRCP (0.50) | CA1CA2KDM4EMAPTALDH1A1 | |
| SCHEMBL30804802 | 0.81 | ALDH1A1 (0.38) | DRD1MAPK1DRD2DRD4CYP2D6 | |
| SCHEMBL28267065 | 0.81 | PNMT (0.37) | DRD1MAPK1DRD2DRD4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8081587 | 0.81 | GAA (0.51) | CA1CA2KDM4EMAPTALDH1A1 | |
| SCHEMBL11574603 | 0.80 | CA1 (0.43) | CA1CA2KDM4EMAPTALDH1A1 | |
| SCHEMBL4746005 | 0.79 | CYP2D6 (0.34) | DRD1MAPK1DRD2DRD4CYP2D6 | |
| SCHEMBL2695009 | 0.79 | ALDH1A1 (0.37) | KDM4EMAPTALDH1A1GAA | |
| SCHEMBL7242610 | 0.74 | CA1 (0.42) | CA1CA2 | |
| SCHEMBL29383585 | 0.74 | ALDH1A1 (0.45) | MAPTTP53ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251919-A1 | POLYARYLENE-BASED COPOLYMER AND USES THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-2489690-A1 | POLYARYLENE COPOLYMER AND USES THEREOF | Sumitomo Chemical Company Limited (JP) | 2012-08-22 | — | — | EP | disclosed |
| CN-102105506-A | Polymer, polyarylene block copolymer, polyelectrolyte, polyelectrolyte membrane, and fuel cell | SUMITOMO CHEMICAL CO | 2011-06-22 | — | — | CN | disclosed |
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1335720-A1 | SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | Bayer Aktiengesellschaft (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-6498183-B1 | TREATMENT AND PROPHYLAXIS OF DISORDERS CAUSED BY HERPES VIRUSES, IN PARTICULAR HUMAN CYTOMEGALOVIRUS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-24 | — | — | US | disclosed |
| WO-2002036115-A1 | SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1177171-A1 | SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS | Bayer Aktiengesellschaft (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000066553-A1 | SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | HTR6, SLC6A4, AANAT | CA1 853/4885CA2 1609/4885DRD1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.